logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
Showing 1 - 5 of 5 Items
Showing 1 - 5 of 5 Items
Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.
  • Current Page (5)
  • CSV
  • BibTeX
  • EndNote
  • All Results (5)
  • CSV
  • BibTeX
  • EndNote
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country multidrug-resistant/rifampicin-resistant tuberculosis cohort

Khan U, Rich M, Franke MF, Lachenal N, Ahmed S,  et al.
2025-08-01 • Clinical Infectious Diseases
2025-08-01 • Clinical Infectious Diseases

BACKGROUND

The 2022 World Health Organization (WHO) guidelines on multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) recommend 6 months of bedaqu...

Journal Article
|
Review
Journal Article
|
Research
Journal Article
|
Research
Technical Report
|
Study report

Clinical best practices for caring for people with expanded resistance to newer TB drugs

Nkomo T, Udwadia Z, Vambe D, van Rie A, Thi S,  et al.
2025-06-13 • IJTLD OPEN
2025-06-13 • IJTLD OPEN

BACKGROUND

Strains of Mycobacterium tuberculosis

The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country MDR/RR-TB cohort

Khan U, Rich M, Franke M, Lachenal N, Ahmed S,  et al.
2024-12-10 • Clinical Infectious Diseases
2024-12-10 • Clinical Infectious Diseases

BACKGROUND

The 2022 WHO guidelines on multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) recommend six months of bedaquiline (Bdq) in the all-oral 9-month shorter regimen ...

Culture conversion at 6 months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

Seung KJ, Khan P, Franke MF, Ahmed S, Aiylchiev S,  et al.
2020-07-11 • Clinical Infectious Diseases
2020-07-11 • Clinical Infectious Diseases

Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observati...

endTB interim analysis report - Bedaquiline- and delaminid- containing regimens achieve excellent interim treatment response without safety concerns

Atwood S, Avagyan N, Bastard M, Cain M, Collin S,  et al.
2018-07-01
2018-07-01